What You Should Know:
– Today, Medidata, a Dassault Systèmes company, is announcing technology enhancements that address key issues in clinical trial management and oversight.
– These enhancements are to Medidata Detect and Rave CTMS (Clinical Trial Management System), which will improve both data oversight and reporting for sponsors and contract research organizations (CROs) in two meaningful ways: how they comprehensively monitor their trial data, and how they visualize those data to make faster decisions.
Medidata Detect and Rave CTMS
– Medidata Detect provides end-to-end data and risk surveillance, giving cross-functional operational teams the ability to monitor and mitigate risks to patient safety and data integrity. This release has created an entirely new role-based user experience, with four unique modules for data review, data analyses, site performance monitoring and protocol risk monitoring.
– Visual Analytics for Rave CTMS is a powerful new data visualization tool that allows users to quickly and easily navigate, explore, and combine data through intuitive visuals, charts and tables. With this launch, study teams have enormous flexibility to visualize all available data within Rave CTMS, and interrogate them in ways that make the most sense for them and for their organization.
Both offerings are part of Medidata’s award-winning Digital Oversight Solution, which has been shown to reduce on-site monitoring days by 33% per site/year (a total of four monitoring days), with no impact to study quality. Medidata’s Digital Oversight Solution unifies risk management, centralized monitoring, remote monitoring and a robust CTMS on one platform. The unified solutions move teams away from delayed, reactive methodologies to proactive and predictive strategies, and supports the execution of decentralized and hybrid trials by ensuring no information is lost, dropped or without clinical context.
